Free shipping on all orders over $ 500


Cat. No. M5246
EW-7197 Structure


Size Price Availability Quantity
10mM*1mL In DMSO USD 120 In stock
5mg USD 137 In stock
10mg USD 225 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: In HaCaT (3TP-luc) and 4T1 (3TP-luc) stable cells, 12b potently inhibits the TGF-β1-induced luciferase reporter activity with IC50 of 16.5 and 12.1 nM, respectively. EW-7197 inhibits TGFβ-induced Smad2 or Smad3 phosphorylation and the epithelial-to-mesenchymal transition (EMT) in TGFβ-treated breast cancer cells. In addition, EW-7197 also abrogates TGFβ1-induced tumor cell migration and invasion in breast cells. In vivo: In rats, EW-7197 shows an oral bioavailability of 51% with high systemic exposure (AUC) of 1426 ng×h/mL and maximum plasma concentration (Cmax) of 1620 ng/mL. EW-7197 also shows low toxicity on the cardiovascular system, central nervous system, and respiratory system. In a mouse B16 melanoma model, EW-7197 (2.5 mg/kg daily p.o.) suppresses the progression of melanoma with enhanced cytotoxic T-lymphocyte (CTL) responses. EW-7197 enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice.

Cell Experiment
Cell lines 4T1 and MCF10A cells
Preparation method Cells are seeded in 96 well plate and treated with indicated concentrations of EW-7197 in 0.2% HI-FBS medium for 72 h. Cells are dried after incubation with 10% TCA in media. Then, cells are incubated with 0.4% SRB (Sulforhodamine B) in 1% acetic acid for 30 min. After washing with 1% glacial acetic acid, bounded dye is released in 10 mM Tris buffer (pH 10.5) for 30 min. Absorbance is measured at 570 nm.
Concentrations ~5 μM
Incubation time 72 hours
Animal Experiment
Animal models Mouse B16 melanoma model
Formulation Artificial gastric fluid formulation (vehicle; ddH2O 900 mL, conc. HCl 7 mL, NaCl 2.0 g, pepsin 3.2 g).
Dosages 2.5 mg/kg daily
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 399.42
Formula C22H18FN7
CAS Number 1352608-82-2
Purity >98%
Solubility 69 mg/mL in DMSO
Storage at -20°C

EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.
Park SA, et al. Cell Mol Life Sci. 2015 May;72(10):2023-39. PMID: 25487606.

EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
Son JY, et al. Mol Cancer Ther. 2014 Jul;13(7):1704-16. PMID: 24817629.

Related TGF-beta/Smad Products

SRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.


ITD-1 is a selective inhibitor of TGF-β signaling (IC50 ~ 0.4-0.8 μM).


R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5nM, an approximately 5000-fold more selectivity for ALK5 than p38 mitogen-activated protein kinase (MAPK).


LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor.

SRI-011381 hydrochloride

SRI-011381 hydrochloride is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.

Abmole Inhibitor Catalog 2017

Keywords: EW-7197, Vactosertib supplier, TGF-beta/Smad, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.